Xue Wei

Standing Committee Member of the Chinese Urological Association, Chairman of the Shanghai Urological Association, Director of the Shanghai Urological Clinical Quality Control Center, Standing Committee Member of the Chinese Medical Doctor Association Urological Association, Deputy Leader of the Minimally Invasive Surgery Group of the Chinese Urological Association, Vice Chairman of the Urology Branch of the China International Exchange and Promotion Association for Medical and Health Care, Vice Chairman of the Urology Professional Committee of the China Primary Health Care Foundation, Standing Director of the 37th Council of the Shanghai Medical Association, Vice Chairman of the Urological Oncology Professional Committee of the Shanghai Anti-Cancer Association, and Vice Dean of the Institute of Medical Equipment and Technology, Shanghai Jiao Tong University School of Medicine. Shanghai Leading Talent, Shanghai Outstanding Academic Leader, and Shanghai Craftsman. He has long been engaged in clinical and basic research on urogenital tumors, especially prostate tumors. He was among the first in China to perform robot-assisted laparoscopic surgery and has profound expertise in the surgical treatment of prostate tumors, kidney cancer, and bladder tumors. Innovative research has been conducted on a series of technologies for the early diagnosis of prostate cancer. A multidisciplinary collaborative, painless, and precise prostate biopsy daytime model has been established, improving the early diagnosis rate by 30% based on the combination of multi-parameter MRI and targeted biopsy. The team pioneered targeted cryoablation for prostate cancer; designed an original multi-gene molecular diagnostic composition specific to prostate cancer; and led a nationwide multi-center study on molecular subtyping and precision treatment of metastatic prostate cancer, forming a unique Renji Hospital-style comprehensive management model for prostate cancer diagnosis and treatment. In the past five years, the team has secured 12 National Natural Science Foundation of China grants, published over 150 papers, including over 100 SCI-indexed papers, and participated in the compilation of 8 expert consensus statements on prostate cancer diagnosis and treatment in China. As the first author, the team received the First Prize of the Outstanding Scientific Research Achievement Award (Science and Technology) of Higher Education Institutions and the First Prize of the Shanghai Medical Science and Technology Award.